~3% of FDA drugs have unclear mechanisms
Only about 3% of FDA-approved drugs have genuinely unclear mechanisms of action, making an unknown mechanism a meaningful early red flag for any compound.
Snapshot · The Peter Attia Drive
#403 ‒ Peptides: separating scientific promise from marketing hype
Explore episode
Aug 10, 2026
Where this was said
A five-question framework for evaluating peptides and other drugs
At 7:30 · chapter starts 5:30
The episode's intellectual engine is a five-question framework Peter developed for the original AMA and now refines here. The framework is deliberately bias-resistant: it applies equally to compounds Peter believes in and ones he's skeptical of. Question one — is there a viable mechanism? — is arguably the most important. Without a defined molecular target and a plausible downstream chain, claims about 'boosting energy' or 'reducing inflammation' become marketing language rather than biology. A mechanism also identifies failure modes: a drug might not reach the relevant tissue, might move biomarkers without affecting disease, or might have opposing downstream effects. [1] — Peter Attia "Five questions cut through the noise on any peptide: Is there a viable mechanism? Human evidence? Known safety and dosing? A justifiable ri…" 05:43 Only about 3% of FDA-approved drugs have genuinely unclear mechanisms — making unknown mechanisms a meaningful red flag. The remaining four questions address human evidence, safety and dosing, risk-benefit calibration, and whether a better-characterized alternative exists, each designed to force specificity rather than allowing vague, unfalsifiable claims.
The 5-Question Framework for Evaluating Any Peptide
Five questions cut through the noise on any peptide: Is there a viable mechanism? Human evidence? Known safety and dosing? A justifiable risk-benefit? And is there a better-characterized alternative? Run any compound through these and you'll usually have your answer.
30–50% of phase 1 drugs fail to reach phase 2
Even compounds that clear preclinical testing often fail in humans: 30 to 50% of drugs entering phase 1 trials do not advance to phase 2, frequently because human behavior differs from animal models.
Similar snapshots
Wandering mind = unhappy mind (Harvard study)
A large Harvard study found that a wandering mind is an unhappy mind — people report greater happiness when their attention is tethered to the present, even if the task is unpleasant.
Microplastic overestimate: gloves contaminated tests
A key study finding that we have a 'credit card's worth of plastic' in our bodies was likely skewed because researchers used nitrile gloves that shed plastic particles onto the microplastic detector.
Hyperactive amygdala + frayed PFC link
Emotionally sensitive people have a hyperactive amygdala, an underactive prefrontal cortex, and a frayed connection between the two — making emotional regulation structurally harder.
RSD visible in children as young as 2–3 years old
Rejection sensitivity can be observed as early as age 2 or 3, suggesting it has strong developmental and likely genetic roots.
Mindfulness reduces brain activation — Yale study
A Yale study found that non-judgmental observation of emotions — without rushing to resolve them — reduces activation in the brain, making it a powerful regulation tool.
Psychological immune system works strongest on irreversible decisions
Dan Gilbert's research found that the psychological immune system — the brain's ability to justify and find satisfaction in choices — activates most powerfully when a decision is perceived as irreversible.
Maximizers earn more but are less happy than satisficers
Barry Schwartz's research found that maximizers — people who try to optimize every decision — tend to achieve objectively better outcomes but report lower happiness than satisficers who choose 'good enough.'
People regret inaction more than action long-term
Research consistently shows that while people may initially regret poor decisions, in the long run they regret the decisions they didn't make — inaction — far more than the ones they took.
Brief exposure to 10 attractive faces reduced relationship satisfaction
A study showed that men in committed relationships who briefly viewed 10 attractive women's faces reported a measurable decrease in relationship satisfaction immediately afterward, illustrating evolutionary mismatch with modern media.
